Lessons learned from gene therapy concerning and the use of integrating vectors and the possible risk of insertional oncogenesis

Developments in Biologicals

Volumn 123, Issue , 2006, Pages 29-34

  Cichutek, K ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; RECOMBINANT VACCINE;

COMBINED IMMUNODEFICIENCY; CONFERENCE PAPER; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; MURINE LEUKEMIA VIRUS; NEOPLASM; RISK FACTOR; STEM CELL TRANSPLANTATION;

GENE THERAPY; GENETIC VECTORS; HUMANS; LEUKEMIA VIRUS, MURINE; NEOPLASMS; RISK FACTORS; SEVERE COMBINED IMMUNODEFICIENCY; STEM CELL TRANSPLANTATION; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 33644614020     PISSN: 14246074     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (10)

1. Ledwith BJ, Manam S, Troilo PJ, Barnum AB, Pauley CJ, Griffiths TG 2nd, Harper LB, Schock HB, Zhang H, Faris JE, Way PA, Beare CM, Bagdon WJ, Nichols WW: Plasmid DNA vaccines: Assay for integration into host genomic DNA, in Brown F, Cichutek K, Robertson J (eds): Development and Clinical Progress of DNA Vaccines. Dev Biol. Basel, Karger, 2000, vol 104, pp 33-43.
2. Wang Z, Troilo PJ, Wang X, Griffiths TG, Pacchione SJ, Barnum AB, Harper LB, Pauley CJ, Niu Z, Denisova L, Follmer TT, Rizzuto G, Ciliberto G, Fattori E, Monica NL, Manam S, Ledwith BJ: Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther 2004; 11 (8): 711-721.
3. Tenenbaum L, Lehtonen E, Monahan PE: Evaluation of risks related to the use of adeno-associated virus-based vectors. Curr Gene Ther 2003; 3 (6): 545-565.
4. Miller DG, Petek LM, Russell DW: Adeno-associated virus vectors integrate at chromosome breakage sites. Nat Genet 2004; 36 (7): 767-773.
5. Dreier G, Cichutek K: German Database of Gene Transfer Clinical Trials. Implementation of a central registry of gene transfer clinical trials in Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2004; 47 (6): 554-558.
6. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P, Deist FL, Fischer A: Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288 (5466): 669-672.
7. Fischer A, Abina SH, Thrasher A, von Kalle C, Cavazzana-Calvo M: LMO2 and gene therapy for severe combined immunodeficiency. N Engl J Med 2004; 350 (24): 2526-2527.
8. Bonini C, Grez M, Traversari C, Ciceri F, Marktel S, Ferrari G, Dinauer M, Sadat M, Aiuti A, Deola S, Radrizzani M, Hagenbeek A, Apperley J, Ebeling S, Martens A, Kolb HJ, Weber M, Lotti F, Grande A, Weissinger E, Bueren JA, Lamana M, Falkenburg JH, Heemskerk MH, Austin T, Kornblau S, Marini F, Benati C, Magnani Z, Cazzaniga S, Toma S, Gallo-Stampino C, Introna M, Slavin S, Greenberg PD, Bregni M, Mavilio F, Bordignon C: Safety of retroviral gene marking with a truncated NGF receptor. Nat Med. 2003; 9 (4): 367-369.
9. Gene Therapy Expert Group of the Committee for Proprietary Medical Products (CPMP): European Agency for the Evaluation of Medical Products. Insertional mutagenesis and oncogenesis: update from non-clinical and clinical studies. Gene Therapy Expert Group of the Committee for Proprietary Medical Products (CPMP), European Agency for the Evaluation of Medical Products - June 2003 meeting. J Gene Med 2004; 6(1): 127-129.
10. CPMP Position Statement On the Use of Tumourigenic Cell Lines of Human Origin For the Production of Biological and Biotechnological Medicinal Products (CPMP/BWP/1143/00).